Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for NATCOPHARM
Revenue projections for NATCOPHARM

NATCO Pharma Limited is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.

Financial Ratios:

currentRatio 4.09800
forwardPE 21.80994
debtToEquity 3.01200
earningsGrowth -0.23500
revenueGrowth -0.00600
grossMargins 0.82408
operatingMargins 0.38650
trailingEps 85.94000
forwardEps 38.14545

NATCOPHARM's current ratio of 4.098 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that NATCOPHARM is financially well-prepared to meet its liabilities without difficulty.
NATCO Pharma Limited's Forward PE is well-positioned, indicating the stock price is favorable compared to its earnings. This suggests the stock is not overpriced and offers room for growth, making it an attractive option for investors looking for future value appreciation.
NATCO Pharma Limited's low growth in both earnings and revenue signals a potential profit decline. This could be a sign of financial trouble, suggesting that the company's profitability might shrink in the near future.
Positive gross and operating margins for NATCO Pharma Limited demonstrate the company's profitability. These margins reflect strong financial performance, with efficient operations contributing to the company's ability to generate consistent profits.
With forward EPS less than trailing EPS, NATCOPHARM is expected to see reduced earnings. This suggests the company may face profitability challenges in the current financial year compared to the previous one.

Price projections:

Price projections for NATCOPHARM
Price projections for NATCOPHARM

NATCOPHARM's price has consistently hovered near the lower end of price projections. This trend suggests that the stock is underperforming relative to analyst expectations, indicating a potential lack of momentum for upward movement in the near future.

Insider Transactions:

Insider Transactions for NATCOPHARM
Insider Transactions for NATCOPHARM


There were 9 transactions selling NATCOPHARM stock, with prevailing market price of 1145.661112467448.2 NATCO Pharma Limited stock purchases took place, with market price of 851.625.The recent trend of increased buying at NATCOPHARM's current price levels may indicate a favorable market sentiment. This could point to a positive outlook for the stock, as investors show growing confidence through higher buy activity.

Recommendation changes over time:

Recommendations trend for NATCOPHARM
Recommendations trend for NATCOPHARM


Analysts have not provided a clear buy or sell recommendation for NATCOPHARM, painting a mixed picture of the stock's future. Investors may need to rely on a broader range of market insights to determine the best course of action for their portfolios.